CENTESSA PHARMACEUTICALS-ADR (CNTA) Stock Overview
USA - NASDAQ:CNTA - US1523091007 - ADR
CNTA Key Statistics, Chart & Performance
The current stock price of CNTA is 23.28 USD. In the past month the price decreased by -2.88%. In the past year, price increased by 50.19%.
CNTA Latest News, Press Relases and Analysis
CNTA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.59 | 403.98B | ||
| AMGN | AMGEN INC | 13.57 | 159.34B | ||
| GILD | GILEAD SCIENCES INC | 15.69 | 150.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.17 | 109.33B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.94B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.81 | 61.98B | ||
| ARGX | ARGENX SE - ADR | 88.4 | 50.13B | ||
| INSM | INSMED INC | N/A | 33.90B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.06 | 34.44B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.54B | ||
| NTRA | NATERA INC | N/A | 25.81B | ||
| BIIB | BIOGEN INC | 9.23 | 21.66B |
Related stock screener links
About CNTA
Company Profile
Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. The company is headquartered in Altrincham, Cheshire and currently employs 98 full-time employees. The company went IPO on 2021-05-28. The firm is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. The company also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
Company Info
CENTESSA PHARMACEUTICALS-ADR
3rd Floor, 1 Ashley Road
Altrincham CHESHIRE GB
CEO: Saurabh Saha
Employees: 98
Phone: 447391789784
CENTESSA PHARMACEUTICALS-ADR / CNTA FAQ
What is the stock price of CENTESSA PHARMACEUTICALS-ADR today?
The current stock price of CNTA is 23.28 USD. The price increased by 2.37% in the last trading session.
What is the ticker symbol for CENTESSA PHARMACEUTICALS-ADR stock?
The exchange symbol of CENTESSA PHARMACEUTICALS-ADR is CNTA and it is listed on the Nasdaq exchange.
On which exchange is CNTA stock listed?
CNTA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CENTESSA PHARMACEUTICALS-ADR stock?
20 analysts have analysed CNTA and the average price target is 33.49 USD. This implies a price increase of 43.86% is expected in the next year compared to the current price of 23.28. Check the CENTESSA PHARMACEUTICALS-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CENTESSA PHARMACEUTICALS-ADR worth?
CENTESSA PHARMACEUTICALS-ADR (CNTA) has a market capitalization of 3.12B USD. This makes CNTA a Mid Cap stock.
How many employees does CENTESSA PHARMACEUTICALS-ADR have?
CENTESSA PHARMACEUTICALS-ADR (CNTA) currently has 98 employees.
What are the support and resistance levels for CENTESSA PHARMACEUTICALS-ADR (CNTA) stock?
CENTESSA PHARMACEUTICALS-ADR (CNTA) has a support level at 22.31. Check the full technical report for a detailed analysis of CNTA support and resistance levels.
Should I buy CENTESSA PHARMACEUTICALS-ADR (CNTA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CNTA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CNTA, evaluating the profitability, health, valuation and growth aspects
- CENTESSA PHARMACEUTICALS-ADR (CNTA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CENTESSA PHARMACEUTICALS-ADR (CNTA) Sales and EPS estimates to see what analysts future expectations are.
- CENTESSA PHARMACEUTICALS-ADR (CNTA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CENTESSA PHARMACEUTICALS-ADR (CNTA) Insider and Institutional Ownership to learn about the owners and their transactions.
- CENTESSA PHARMACEUTICALS-ADR (CNTA) Stock Chart to make your own analysis
- CENTESSA PHARMACEUTICALS-ADR (CNTA) Latest news and press-releases to stay up to date.
Does CENTESSA PHARMACEUTICALS-ADR (CNTA) stock pay dividends?
CNTA does not pay a dividend.
When does CENTESSA PHARMACEUTICALS-ADR (CNTA) report earnings?
CENTESSA PHARMACEUTICALS-ADR (CNTA) will report earnings on 2025-11-10.
What is the Price/Earnings (PE) ratio of CENTESSA PHARMACEUTICALS-ADR (CNTA)?
CENTESSA PHARMACEUTICALS-ADR (CNTA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.53).
What is the Short Interest ratio of CENTESSA PHARMACEUTICALS-ADR (CNTA) stock?
The outstanding short interest for CENTESSA PHARMACEUTICALS-ADR (CNTA) is 4.54% of its float. Check the ownership tab for more information on the CNTA short interest.
CNTA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CNTA. When comparing the yearly performance of all stocks, CNTA is one of the better performing stocks in the market, outperforming 92.58% of all stocks.
CNTA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CNTA. While CNTA seems to be doing ok healthwise, there are quite some concerns on its profitability.
CNTA Financial Highlights
Over the last trailing twelve months CNTA reported a non-GAAP Earnings per Share(EPS) of -1.53. The EPS increased by 1.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -46.9% | ||
| ROE | -66.92% | ||
| Debt/Equity | 0.32 |
CNTA Forecast & Estimates
20 analysts have analysed CNTA and the average price target is 33.49 USD. This implies a price increase of 43.86% is expected in the next year compared to the current price of 23.28.